Veralipride
From Wikipedia, the free encyclopedia
 |
|
|
Veralipride
|
|
| Systematic (IUPAC) name | |
| 2,3-Dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C17H25N3O5S |
| Mol. mass | 383.4625 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
withdrawn |
| Routes | Oral |
Veralipride (INN; brand names Agreal and Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride has never gained approval in the United States.
On September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA).
On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[1]
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
